Photo Credit: IANS
IANSLive
Hyderabad, May 3 (IANS) A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
For susbcription contact
New stem cell-based therapy by University of Hyderabad startup may speed up COVID recovery
The research conducted on HEMATO UC-MSCs recommends that it must be administered as two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart .
Share Via Email
| A+A A- By Express News Service
HYDERABAD: A biotech startup incubated at the University of Hyderabad (UoH) has developed a new stem cell-based therapy for the treatment of COVID-19 patients. The therapy been found to significantly reduce the cytokine storm with improved patient survival and time of recovery.
The new therapy is based on Umbilical Cord (UC) tissue-harvested and clinically processed adult Mesenchymal Stem Cells (MSCs). The therapy, developed by Transcell Oncologics, has already been used as part of the treatment regimen by doctors treating Covid-19 patients in a few hospitals across Hyderabad, Warangal and Delhi.
UoH startup develops stem cell-based treatment for COVID-19
By IANS| Posted by Neha | Updated: 3rd May 2021 11:15 pm IST University of Hyderabad
Hyderabad: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for COVID-19 patients.
Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 ‘cytokine storm’, with significantly improved patient survival and time to recovery.